Regulators require that the cell culture-based bioprocesses used for manufacturing protein therapeutics, vaccines, and cell and gene therapy products be tested to ensure they are mycoplasma-free. Traditionally, testing was done using a culture-based, 28-day mycoplasma test. More recently, PCR-based alternatives have evolved, driven by an industry move to shorten lot disposition cycles and the emergence of cell-based therapeutics that require a more rapid test. Recent regulatory guidance allows manufacturers to select rapid tests – as long as they are validated to demonstrate sensitivity and specificity that are comparable to or that improve upon traditional tests. The big question: how should manufacturers respond?
In this eBook, discover how the MycoSEQ™ Mycoplasma Detection System is being used in the real world to accelerate testing. This eBook includes information, case studies, user tips, and more.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
